BETA BIONICS INC (BBNX) Stock Price & Overview
NASDAQ:BBNX • US08659B1026
Current stock price
The current stock price of BBNX is 10.39 USD. Today BBNX is up by 2.77%. In the past month the price decreased by -23.32%. In the past year, price decreased by -29.18%.
BBNX Key Statistics
- Market Cap
- 461.108M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.94
- Dividend Yield
- N/A
BBNX Stock Performance
BBNX Stock Chart
BBNX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BBNX. When comparing the yearly performance of all stocks, BBNX is a bad performer in the overall market: 93.73% of all stocks are doing better.
BBNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BBNX. No worries on liquidiy or solvency for BBNX as it has an excellent financial health rating, but there are worries on the profitability.
BBNX Earnings
On February 17, 2026 BBNX reported an EPS of -0.29 and a revenue of 32.12M. The company beat EPS expectations (31.57% surprise) and beat revenue expectations (4.13% surprise).
BBNX Forecast & Estimates
17 analysts have analysed BBNX and the average price target is 23.83 USD. This implies a price increase of 129.36% is expected in the next year compared to the current price of 10.39.
For the next year, analysts expect an EPS growth of -0.29% and a revenue growth 34.76% for BBNX
BBNX Groups
Sector & Classification
BBNX Financial Highlights
Over the last trailing twelve months BBNX reported a non-GAAP Earnings per Share(EPS) of -1.94. The EPS decreased by -41.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.27% | ||
| ROE | -25.45% | ||
| Debt/Equity | 0 |
BBNX Ownership
BBNX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 18.81 | 187.913B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.2 | 170.203B | ||
| SYK | STRYKER CORP | 22.27 | 129.047B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.77 | 101.721B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.52 | 49.099B | ||
| IDXX | IDEXX LABORATORIES INC | 38.71 | 45.48B | ||
| BDX | BECTON DICKINSON AND CO | 11.69 | 45.453B | ||
| RMD | RESMED INC | 18.8 | 33.857B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.69 | 32.053B | ||
| DXCM | DEXCOM INC | 25.27 | 25.116B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.99 | 18.115B | ||
| HOLX | HOLOGIC INC | 15.3 | 16.79B | ||
| PODD | INSULET CORP | 34 | 16.619B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BBNX
Company Profile
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 420 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
Company Info
IPO: 2025-01-30
BETA BIONICS INC
11 Hughes
Irvine CALIFORNIA US
Employees: 420
Phone: 18002462677
BETA BIONICS INC / BBNX FAQ
What does BBNX do?
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 420 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
What is the stock price of BETA BIONICS INC today?
The current stock price of BBNX is 10.39 USD. The price increased by 2.77% in the last trading session.
Does BBNX stock pay dividends?
BBNX does not pay a dividend.
What is the ChartMill rating of BETA BIONICS INC stock?
BBNX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about BETA BIONICS INC (BBNX) stock?
17 analysts have analysed BBNX and the average price target is 23.83 USD. This implies a price increase of 129.36% is expected in the next year compared to the current price of 10.39.
Is BETA BIONICS INC (BBNX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BBNX.